What is Leerink Partnrs' Estimate for Repligen Q4 Earnings?

Key Points

• Leerink Partners has revised its Q4 2025 EPS estimate for Repligen to $0.52, slightly up from $0.51, with the full-year earning consensus expected at $1.72 per share.
• Several research firms have varying price targets for Repligen, with a range from $130 to $205, and a general consensus rating of "Moderate Buy".
• Repligen's stock has experienced a recent decline of 5.0%, currently trading at approximately $113.54, with significant volatility noted over the past year.

Repligen Corporation (NASDAQ:RGEN - Free Report) - Investment analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for Repligen in a report issued on Thursday, September 11th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $0.52 per share for the quarter, up from their previous estimate of $0.51. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's FY2026 earnings at $2.11 EPS.

A number of other research firms also recently weighed in on RGEN. Wells Fargo & Company reduced their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target for the company in a research note on Tuesday, July 22nd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 price target on shares of Repligen in a research note on Tuesday, September 2nd. Evercore ISI dropped their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Repligen Stock Down 5.0%

RGEN opened at $113.54 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The firm's fifty day moving average is $120.73 and its 200 day moving average is $127.58. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of -454.14, a price-to-earnings-growth ratio of 2.09 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. During the same quarter in the previous year, the company earned $0.40 earnings per share. The business's quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quantinno Capital Management LP grew its stake in shares of Repligen by 80.0% during the 4th quarter. Quantinno Capital Management LP now owns 3,523 shares of the biotechnology company's stock worth $507,000 after purchasing an additional 1,566 shares during the period. ProShare Advisors LLC grew its stake in shares of Repligen by 7.4% during the 4th quarter. ProShare Advisors LLC now owns 2,438 shares of the biotechnology company's stock worth $351,000 after purchasing an additional 167 shares during the period. Polar Asset Management Partners Inc. grew its stake in shares of Repligen by 76.9% during the 4th quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company's stock worth $993,000 after purchasing an additional 3,000 shares during the period. Raiffeisen Bank International AG acquired a new position in shares of Repligen during the 4th quarter worth $29,000. Finally, Two Sigma Advisers LP grew its stake in Repligen by 6.7% in the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company's stock valued at $19,403,000 after acquiring an additional 8,500 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction on Friday, August 8th. The stock was bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.